What Is End-of-Life Care Like for Advanced Merkel Cell Carcinoma?

The short answer: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer that spreads to lymph nodes and distant organs rapidly. Immunotherapy (avelumab, pembrolizumab) has transformed outcomes, but in treatment-resistant disease, end-of-life care addresses skin tumor management, lymphedema, pain, and the rapidly progressive course. Early palliative integration is recommended.

Understanding Advanced Merkel Cell Carcinoma

Merkel cell carcinoma (MCC) is a rare neuroendocrine skin cancer with approximately 3,000 new US cases per year. It is much more aggressive than common skin cancers — with a high rate of lymph node spread and distant metastasis. Risk factors include immunosuppression, UV exposure, and Merkel cell polyomavirus (MCPyV) infection.

The advent of checkpoint immunotherapy (avelumab/Bavencio and pembrolizumab/Keytruda) has significantly improved outcomes for metastatic MCC — a proportion of patients achieve durable responses. However, some patients do not respond or eventually progress.

Symptoms in Advanced MCC

Skin/subcutaneous tumors: Multiple lesions that may ulcerate, bleed, or become infected; wound management challenges similar to other advanced skin cancers
Lymphedema: Extensive lymph node involvement causes limb swelling
Distant metastases: MCC spreads to liver, lung, bone, and brain; symptoms depend on metastatic sites
Pain: Local tumor pain, bone pain from metastases, neuropathic pain
Fatigue: Profound with advanced disease and treatment side effects
Immunotherapy side effects: Ongoing immune-related adverse events may be significant

Palliative Care Priorities

Skin tumor care: Wound management protocols; radiation for symptomatic skin/nodal lesions; palliative radiation for bleeding or painful sites
Pain management: Multimodal analgesia for local tumor and distant metastatic pain
Lymphedema: Specialist lymphedema therapy; compression; skin care to prevent cellulitis
Fatigue: Energy conservation; addressing correctable contributors
Psychosocial support: Visible skin tumors and rapid progression cause significant distress; psychological support and peer connection important

Goals of Care in MCC

Because immunotherapy has transformed MCC outcomes for some patients, distinguishing between "likely to respond" and "unlikely to respond" to ongoing treatment is important. For patients with treatment-resistant disease, early goals-of-care conversations allow informed decisions about prioritizing quality of life. The Merkel Cell Carcinoma Research Foundation provides patient community and specialist resources.

Frequently Asked Questions

What is the prognosis for metastatic Merkel cell carcinoma?

Metastatic MCC historically had a very poor prognosis with median survival under a year. Immunotherapy has significantly improved outcomes — approximately 30-40% of patients with avelumab or pembrolizumab achieve durable responses lasting years. However, for patients who don't respond or progress through immunotherapy, prognosis remains poor. Individual prognosis should be discussed with an MCC specialist.

Can Merkel cell carcinoma recur after seeming to respond to immunotherapy?

Yes. Even patients who achieve complete response can have late recurrences, sometimes years after apparent remission. Ongoing surveillance is important. Recurrence after immunotherapy typically means the tumor has developed resistance, and treatment options are more limited at that point.

Yes — approximately 80% of MCC cases are caused by Merkel cell polyomavirus (MCPyV). MCPyV-positive MCC tends to have a better prognosis and stronger response to immunotherapy. The remaining 20% (MCPyV-negative, typically UV-related) tend to have a worse prognosis. Immunostaining for MCPyV proteins can guide treatment decisions.

How should skin tumors from MCC be managed palliatively?

Skin tumors in MCC require wound care similar to other advanced skin cancers: non-adherent dressings, antimicrobial coverage for infected wounds, charcoal dressings for odor management. Palliative radiation can be very effective for controlling symptomatic skin or nodal disease. Dermatology-trained wound nursing improves care quality significantly.

Where can I find MCC specialists?

MCC, while rare, is best treated at academic cancer centers with skin cancer programs. The Merkel Cell Carcinoma Research Foundation (merkelcell.org) at the University of Washington maintains a specialist directory and patient resource center. University of Washington, Memorial Sloan Kettering, and MD Anderson have published extensively on MCC and see significant numbers of patients.

Renidy connects grieving families with compassionate death doulas and AI-powered funeral planning tools. Try our free AI funeral planner or find a death doula near you.